DOCSLIB.ORG

Participant Manual DRE 7-Day Session 22 – Overview of Signs and Symptoms

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Participant Manual DRE 7-Day Session 22 – Overview of Signs and Symptoms Participant Manual DRE 7-Day Session 22 – Overview of Signs and Symptoms Session 22 – Overview of Signs and Symptoms 60 Minutes Notes:_______________________________________________ _____________________________________________________ Session 22 _____________________________________________________ Overview of _____________________________________________________ Signs and Symptoms _____________________________________________________ _____________________________________________________ _____________________________________________________ _____________________________________________________ _____________________________________________________ Drug Recognition Expert Course Session 22 – Overview of Signs and Symptoms Notes:_______________________________________________ Learning Objectives _____________________________________________________ • Describe the possible effects that may _____________________________________________________ be observed in each major indicator of drug impairment _____________________________________________________ • Identify the effects that will most likely _____________________________________________________ be observed with subjects under the _____________________________________________________ influence of each drug category _____________________________________________________ _____________________________________________________ _____________________________________________________ Drug Recognition Expert Course 22-2 Upon successfully completing this session the participant will be able to: • Describe the possible effects that may be observed in each major indicator of drug impairment. • Identify the effects that will most likely be observed with subjects under the influence of each drug category. CONTENT SEGMENTS LEARNING ACTIVITIES A. The Major Indicators and their Instructor-Led Presentations Possible Effects B. Effects Associated with the Drug Interactive Discussions Categories HS 172 R5/13 1 of 28 Session 22 – Overview of Signs and Symptoms Session 22 – Overview of Signs and Symptoms Notes:_______________________________________________ DREDRE MajorMajor andand GeneralGeneral IndicatorsIndicators _____________________________________________________ _____________________________________________________ •• MajorMajor Indicators:Indicators: PhysiologicalPhysiological IndicatorsIndicators _____________________________________________________ •• GeneralGeneral Indicators:Indicators: ObservationalObservational andand _____________________________________________________ BehavioralBehavioral IndicatorsIndicators _____________________________________________________ _____________________________________________________ _____________________________________________________ _____________________________________________________ Drug Recognition Expert Course 22-3 Drug Recognition Expert Course 22-3 DRE Major and General Indicators • For DRE purposes, Major Indicators are physiological signs that are specifically addressed and are, for the most part, involuntary; reflecting the status of the Central Nervous System homeostasis. • For DRE purposes, General Indicators are behaviors or observations of the subject that are observed and not specifically tested for. Both are of equal value in making a decision in the totality of the evaluation. HS 172 R5/13 2 of 28 Session 22 – Overview of Signs and Symptoms Notes:_______________________________________________ Major Physiological Indicators of _____________________________________________________ Drug Impairment • Horizontal Gaze Nystagmus _____________________________________________________ • Vertical Gaze Nystagmus _____________________________________________________ • Lack of Convergence • Pupil Size _____________________________________________________ • Reaction to Light _____________________________________________________ • Pulse Rate • Blood Pressure _____________________________________________________ • Body Temperature _____________________________________________________ • Muscle Tone _____________________________________________________ Drug Recognition Expert Course 22-4 A. The Major Physiological Indicators and Their Possible Effects Major Physiological Indicators of Drug Impairment The major physiological indicators of drug impairment are (point to the major indicators on the matrix): • Horizontal Gaze Nystagmus • Vertical Gaze Nystagmus • Lack of Convergence • Pupil Size • Reaction to Light • Pulse Rate • Blood Pressure • Body Temperature • Muscle Tone HS 172 R5/13 3 of 28 Session 22 – Overview of Signs and Symptoms Notes:_______________________________________________ Possible Effects: HGN _____________________________________________________ • Possible effects that might be observed _____________________________________________________ with Nystagmus _____________________________________________________ • With Horizontal Gaze Nystagmus, there _____________________________________________________ are only two possible effects that might be observed _____________________________________________________ _____________________________________________________ _____________________________________________________ _____________________________________________________ Drug Recognition Expert Course 22-5 Possible Effects: HGN Possible effects that might be observed with Nystagmus; With Horizontal Gaze Nystagmus, there are only two possible effects that might be observed. • Either HGN will be present; • Or it will be none (meaning that it is not present). There is no drug that stops Horizontal Gaze Nystagmus. Some drugs cause HGN to be present, others do not; but there is no drug that “cures” HGN. Session 22 – Overview of Signs and Symptoms Notes:_______________________________________________ Possible Effects: VGN _____________________________________________________ What are the possible effects we might _____________________________________________________ observe with Vertical Gaze Nystagmus? _____________________________________________________ • With Vertical Gaze Nystagmus, there are _____________________________________________________ also only two possible effects _____________________________________________________ _____________________________________________________ _____________________________________________________ _____________________________________________________ Drug Recognition Expert Course 22-6 Possible Effects: VGN With Vertical Gaze Nystagmus, there are also only two possible effects. • Either it will be present; • Or it will be none (meaning that it is not present). HS 172 R5/13 4 of 28 Session 22 – Overview of Signs and Symptoms Notes:_______________________________________________ Possible Effects: LOC _____________________________________________________ What effects might we observe with Lack _____________________________________________________ of Convergence? _____________________________________________________ • For Lack of Convergence, there are also _____________________________________________________ only two possible effects _____________________________________________________ _____________________________________________________ _____________________________________________________ _____________________________________________________ Drug Recognition Expert Course 22-7 Possible Effects: LOC For Lack of Convergence, there are also only two possible effects. • Either Lack of Convergence will be present; • Or it will be none (meaning that it is not present). Just as with Nystagmus, there is no drug that “cures” Lack of Convergence. Session 22 – Overview of Signs and Symptoms Notes:_______________________________________________ Possible Effects: Pupil Size _____________________________________________________ _____________________________________________________ What effects might we observe with Pupil Size? _____________________________________________________ • For Pupil Size, there are three possible _____________________________________________________ effects _____________________________________________________ _____________________________________________________ _____________________________________________________ _____________________________________________________ Drug Recognition Expert Course 22-8 Possible Effects: Pupil Size For Pupil Size, there are three possible effects that might be seen. • The pupils might be normal (within the DRE average ranges). • Or, the pupils might be dilated. • Or, they might be constricted. HS 172 R5/13 5 of 28 Session 22 – Overview of Signs and Symptoms Notes:_______________________________________________ Possible Effects: Pupil Size (Cont.) _____________________________________________________ What effects might we observe with _____________________________________________________ Pupils’ Reaction to light? _____________________________________________________ • There are a number of effects that might _____________________________________________________ be observed in the pupils’ Reaction to Light _____________________________________________________ _____________________________________________________ _____________________________________________________ _____________________________________________________ Drug Recognition Expert Course 22-9 Possible Effects: Reaction to Light There are a number of effects that might be observed in the pupils’ Reaction to Light. • The pupils might react in a normal manner, i.e. by constricting somewhat in one second or less. • Or, the pupils might react slow, i.e. by constricting somewhat, but requiring
Load more

Recommended publications
  • The Ever-Changing Impaired Driving Landscape
    The Ever-Changing Impaired Driving Landscape Chuck Hayes International Association of Chiefs of Police Impaired Driving Through the Years Commonly referred to as “drunk driving” in early days August 1910 – 1st "drunk driving" arrest (New York City) 1930’s - Police recognize perils of “narcotics” users operating automobiles (California) 1960’s - Illicit drugs and driving emerge 1980’s - Prescription drugs and driving on the rise 2013/Present - MJ DUI cases on the rise 2015/Present - Opiate DUI incidents emerging The Changing Landscape Drugged driving is on the rise Drugs other than alcohol becoming more prevalent in motor vehicle crashes Many on-going national and international efforts to address the problem Drugged Driving Research 2013 – 2014 Roadside Survey of Alcohol and Drug Use by Drivers: Weekend nighttime drivers testing positive for illegal drugs or medications increased from 16.3% in 2007 to 20% in 2013-2014. One in four drivers tested positive for at least one drug that could adversely affect vehicle operation - an increase of 23% from 2007. Police Finding More Drugged Drivers on Pennsylvania Roads CNHI, January 30, 2016 • Almost 4 in 10 DUI arrests in 2014 involved drugs • In 2014, 52,636 people were arrested for DUI – a decease of approximately 1,400 drivers. However, drugged driving arrests increased 20,691 - nearly a 10% increase from the previous year MJ Involvement in Washington Fatal Crashes Average of 12.2% of deceased drivers tested for drugs (2010 – 2013) tested positive for THC Increased to 22.1% in 2014.
    [Show full text]
  • Drug Recognition Expert Condensed Instructor Development Course
    Participant Manual October, 2016 This Page Intentionally Left Blank Drug Recognition Expert Condensed Instructor Development Course Session 1 – Introduction February 2017 Page 1 Drug Recognition Expert Condensed Instructor Development Course Session 1: Introduction to the Drug Recognition Expert (DRE) Condensed Instructor Development Course (IDC) Estimated time for Session 1: 1 Hour (depending on class size) Session Objectives • Using the provided agenda, review course objective and other administrative matters • Using the windowpane exercise, participants will express expectations of the course • Participants are expected to actively engage in course activities Contents A. Welcome B. Facilities, Logistics, and Classroom Conduct C. Course Format D. Introduction E. Final Participation Demonstration F. Questions and/or Concerns Session 1 – Introduction February 2017 Page 2 Drug Recognition Expert Condensed Instructor Development Course A. WELCOME Welcome to the Drug Recognition Expert (DRE) Condensed Instructor Development Course (IDC) Session 1: Introduction _____________________________________________________________________ _____________________________________________________________________ _____________________________________________________________________ _____________________________________________________________________ _____________________________________________________________________ _____________________________________________________________________ _____________________________________________________________________
    [Show full text]
  • (DEC) Program the Drug Evaluation and Classification
    SPECIAL TOPICS SERIES American Prosecutors Research Institute TheThe DrugDrug EvaluationEvaluation andand ClassificationClassification (DEC)(DEC) ProgramProgram TTargetingargeting HardcoreHardcore ImpairedImpaired DriversDrivers American Prosecutors Research Institute 99 Canal Center Plaza, Suite 510 Alexandria,VA 22314 www.ndaa-apri.org Thomas J. Charron President Roger Floren Chief of Staff Stephen K.Talpins Director, National Traffic Law Center Debra Whitcomb Director, Grant Programs and Development George Ross Director, Grants Management This document was produced thanks to a charitable contribution from the Anheuser-Busch Foundation in St. Louis, Missouri. Its support in assisting local prosecutors’ fight against impaired driving is greatly acknowledged.This information is offered for educational purposes only and is not legal advice. Points of view or opinions expressed in this document are those of the authors and do not necessarily represent the official position of the Anheuser-Busch Foundation, the National District Attorneys Association, or the American Prosecutors Research Institute. © 2004 by the American Prosecutors Research Institute, the non-profit research, training and technical assistance affiliate of the National District Attorneys Association. SPECIAL TOPICS SERIES The Drug Evaluation and Classification (DEC) Program Targeting Hardcore Impaired Drivers October 2004 Stephen K.Talpins Director, National Traffic Law Center Chuck Hayes International Association of Chiefs of Police American Prosecutors Research Institute 99 Canal Center Plaza, Suite 510 Alexandria,VA 22314 D EDICATION Our efforts are dedicated to the hundreds of thousands of impaired driving victims and their families and the thousands of professionals and advocates working to alleviate the impaired driving problem. This monograph is dedicated to the following individuals for their tireless efforts to promote traffic safety: Dr.
    [Show full text]
  • Drug Evaluation and Classification Training
    Drug Evaluation and Classification Training “The Drug Recognition Expert School" January 2011 Edition Student Manual DRUG EVALUATION AND CLASSIFICATION TRAINING PROGRAM THE DRUG RECOGNITION EXPERT SCHOOL JANUARY 2011 EDITION U.S. DEPARTMENT OF TRANSPORTATION Transportation Safety Institute National Highway Traffic Safety Administration HS172 R01/11 TABLE OF CONTENTS Session Title I Introduction and Overview II Drugs in Society and in Vehicle Operation III Development and Effectiveness of the DEC Program IV Overview of Drug Evaluation and Classification Procedures V Eye Examinations VI Physiology and Drugs: An Overview VII Examination of Vital Signs VIII Demonstrations of the Evaluation Sequence IX Central Nervous System Depressants X Central Nervous System Stimulants XI Practice: Eye Examinations XII Alcohol Workshop XIII Physician's Desk Reference and Reference Sources XIV Hallucinogens XV Practice: Test Interpretation XVI Dissociative Anesthetics XVII Narcotic Analgesics Mid Course Review XVIII Practice: Test Interpretation XIX Inhalants XX Practice: Vital Signs Examinations HS172 R01/11 XXI Cannabis XXII Overview of Signs and Symptoms XXIII Curriculum Vitae Preparation and Maintenance XXIV Drug Combinations XXV Practice: Test Interpretation XXVI Preparing the Narrative Report XXVII Practice: Test Administration XXVIII Case Preparation and Testimony Review of the DRE School XXIX Classifying a Subject (Role Play) XXX Transition to the Certification Phase of Training HS172 R01/11 SESSION I INTRODUCTION AND OVERVIEW HS172 R01/11 1 SESSION I INTRODUCTION AND OVERVIEW Upon successfully completing this session, the student will be able to: o State the goals and objectives of the course. o Outline the major course content. o Outline the schedule of major course activities. o Outline the contents and arrangements of the student manual.
    [Show full text]
  • 2012 Drug Recognition Expert Section (DRE) Annual Report
    lllllll The 2012 Annual Report of the Drug Recognition Expert Section October 2013 The 2012 Annual Report of the IACP Drug Recognition Section A summary of activities January 1-December 31, 2012 by U.S. states and Canadian provinces who participate in the IACP/NHTSA International Drug Evaluation and Classification Program Contents Letter from the Chair of the Drug Recognition Section 3 Description of the Drug Recognition Expert Insignia 4 The Drug Evaluation and Classification Program: IACP/NHTSA Coordination and Support 5 About the IACP DRE Section: Its Mission and Structure 8 DRE Section Strategic Plan 2006 DRE Section Officers, Former Chairs IACP DECP Staff The DRE Section’s Annual Training Conference About the DECP Technical Advisory Panel 16 Reports from the DECP States and Canada 17 Appendix DECP State Coordinators, IACP Staff 161 and NHTSA Contact Information Members of IACP DECP Technical Advisory Panel 167 DRE Section and TAP Regional Representatives 170 President Third Vice President International Vice President Parliamentarian Craig T. Steckler Ronal W. Serpas Nelson Werlang Garcia Ellen Hanson (retired) Chief of Police Superintendent of Police Chief, Community Policing & Human Chief of Police Fremont Police Department New Orleans Police Department Rights Center Lenexa Police Department Fremont, CA New Orleans, LA Polícia Militar do Distrito Federal Lenexa, KS Brasilia, Brazil Immediate Past President Fourth Vice President Executive Director Walter A. McNeil Terrence Cunningham Vice President-Treasurer Bart R. Johnson Chief of Police Chief of Police Dwight Henninger Alexandria, VA Quincy Police Department Wellesley Police Department Chief of Police Quincy, Florida Wellesley, MA Vail Police Department Deputy Executive Director Vail, CO Chief of Staff First Vice President Vice President at Large James W.
    [Show full text]
  • The Drug Recognition Expert and Impaired Driving Enforcement
    The Drug Recognition Expert and Impaired Driving Enforcement by Sgt. Jamie Boothe School of Law Enforcement Supervision (SLES) Session XXXIV Criminal Justice Institute November 20, 2009 The Drug Recognition Expert and Impaired Driving Enforcement It is a sad but persistent truth that impaired driving impacts the lives of thousands of Americans each and every year. Whether it is the loss of a loved one, a debilitating, life-altering injury, or financial crises brought on by skyrocketing medical costs, there is no escape from the fact that impaired driving changes lives. The only solution to the problem is targeted enforcement aimed at reducing the number of impaired drivers on the highways, and insuring that those who engage in this type of conduct are held accountable for their actions. The Drug Recognition Expert, hereafter referred to simply as the DRE, is an important resource in our efforts to reduce impaired driving, and ultimately save lives. As a DRE, I take great pride and satisfaction in knowing that I am doing everything possible to help in this enormous task. The majority of the information contained within the body of this paper is taken from my own knowledge base and first hand experience in dealing with drug-impaired drivers. To understand how the DRE fulfills their role in impaired driving enforcement, I will examine the prevalence of drug use in society and its impact on traffic safety, the origin and development of the Drug Evaluation and Classification program, how drugs cause impairment, categories of drugs, and the standardized drug evaluation process used by all DREs to determine impairment in drivers.
    [Show full text]
  • Student Manual
    [This page is intentionally left blank] Drug Recognition Expert Course Preliminary School Participant Manual Table of Contents 2015 Curriculum Acknowledgements Preface Page Session 1: Introduction: Preliminary training for the DEC Program • Glossary of Terms Session 2: Overview of the DEC Procedures Session 3: Psychophysical Tests Session 4: Eye Examinations Session 5: Alcohol Workshop Session 6: Examination of Vital Signs Session 7: Overview of Signs and Symptoms Session 8: Alcohol as a Drug Session 9: Preparing for DRE School Session 10: Conclusion of the Preliminary Training Revised: Drug Recognition Expert Preliminary Course 10/2015 Table of Contents Page 1 of 1 [This page is intentionally left blank] Acknowledgements The National Highway Traffic Safety Administration (NHTSA) and the International Association of Chiefs of Police (IACP) would like to thank the following individuals for their contributions in updating and revising the 2015 DRE curricula. Jonlee Anderle, Wyoming Department of Transportation Highway Safety Office Kyle Clark, Institute of Police Technology and Management Don Decker, Nahant MA Police Department Evan Graham, Royal Canadian Mounted Police Chuck Hayes, International Association of Chiefs of Police Mike Iwai, Oregon State Police Pam McCaskill, DOT Transportation Safety Institute, Oklahoma City, OK Bill Morrison, Montgomery County Police Department, MD (Retired) Bill O'Leary, National Highway Traffic Safety Administration Doug Paquette, New York State Police James Roy, Colchester, VT Police Department Joanne Thomka, National Traffic Law Center of the National District Attorneys Association Revised: Drug Recognition Expert Preliminary Course 10/2015 Acknowledgements Page 1 of 1 [This page is intentionally left blank] Preface The Drug Recognition Expert course is a series of three training phases that, collectively, prepare police officers and other qualified persons to serve as drug recognition experts (DRE).
    [Show full text]
  • The Drug Evaluation and Classification (DEC) Program
    Saving Lives and Preventing Crashes The Drug Evaluation and Classification (DEC) Program National District Attorneys Association 1400 Crystal Drive Suite 330 Arlington, VA 22202 www.ndaajustice.org Nelson O. Bunn, Jr., Executive Director National Traffic Law Center A Program of the National District Attorneys Association www.ndaajustice.org/ntlc_home.html Tom Kimball, Program Director This document was funded by: The Foundation for Advancing Alcohol Responsibility (Responsibility.org) is a national not- for-profit organization and a leader in the fight to eliminate drunk driving and underage drinking. Funded by leading distilled spirits companies including Bacardi U.S.A., Inc.; Beam Suntory; Brown-Forman; Constellation Brands, Inc.; DIAGEO; Edrington; Mast-Jägermeister US, Inc.; and Pernod Ricard USA, Responsibility.org has transformed countless lives through programs that bring individuals, families, and communities together to guide a lifetime of conversation around alcohol responsibility and by offering proven strategies to stop impaired driving. © 2018 by the National Traffic Law Center, the traffic law resource center program of the National District Attorneys Association Cover photo: © bst2012 / Adobe Stock The Drug Evaluation and Classification (DEC) Program Saving Lives and Preventing Crashes AUTHORS Steve Talpins Attorney and former Director of the National Traffic Law Center Chuck Hayes Project Manager of the Drug Evaluation and Classification Program, Western Region, International Association of Chiefs of Police Tom Kimball Director, National Traffic Law Center CONTRIBUTORS Tom Page Former Los Angeles Police Department Sergeant Tom Page Kyle Clark Project Manager of the Drug Evaluation and Classification Program, Eastern Region, International Association of Chiefs of Police — DEDICATION — THIS MONOGRAPH IS DEDICATED TO THE VICTIMS OF IMPAIRED DRIVING AND THEIR FAMILIES .
    [Show full text]
  • Drug-Impaired Driving
    “Fighting the Battle Against Impaired Driving” MI Office of Highway Safety Planning March 12, 2008 Ernie Floegel, IACP Officer Jeramey Peters, Auburn Hills PD Drugged Driving? Is it a problem? Who’s doing it? How do we prevent it? New Data – Washington State 2003 – Study by Dr. Barry Logan revealed that 44 percent of drivers killed in crashes in Washington tested positive for alcohol. Of those, 38 percent were also positive for psychoactive drugs and 30 percent of the drivers who were alcohol free, were positive for drugs. (WA DRE Newsletter, 2004) Hand-Sanitizers • 62 % Alcohol • Licking • Rubbing on Gums • Poisonous Huffing • North Little Rock, AR • 16 Year Old Female • Unconscious / Ambulance • Vapor Heavier Then Air – Displaces Oxygen • Knowledge Came From PO / Zamboni • Newark, NJ • 0.12 % • Beer, Vodka, Sambuca & Valium Horseback • Sylvania, Alabama • Midnight / City Street • 40 Year Old Female • Under the Influence of a Controlled Substance, Drug Possession, etc. etc. • Crystal Meth, Marijuana “Cheese”: The New Face of Heroin + = Tylenol PM or generic Black Tar Heroin “Cheese” What is “Cheese”? Black tar heroin combined with crushed Tylenol PM tablets Highly Addictive and very dangerous Tan-colored powder usually snorted through the nose with a tube, straw, or small ballpoint pen Packaged in a small paper bindle or zip lock baggie Can be bought for as little as $2 Popular among Hispanic juveniles, both male and female Has been identified in more than a dozen Dallas ISD secondary and surrounding suburbs Symptoms of Use Drowsiness
    [Show full text]
  • Drug Recognition Expert (DRE) Examination Characteristics Of
    Accident Analysis and Prevention 92 (2016) 219–229 Contents lists available at ScienceDirect Accident Analysis and Prevention jo urnal homepage: www.elsevier.com/locate/aap Drug Recognition Expert (DRE) examination characteristics of cannabis impairment a b c a,∗ Rebecca L. Hartman , Jack E. Richman , Charles E. Hayes , Marilyn A. Huestis a Chemistry and Drug Metabolism, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, 251 Bayview Boulevard Ste 200 Rm 05A721, Baltimore, MD, 21224, USA b Hingham Police Department, 212 Central Street, Hingham, MA 02043, USA c International Association of Chiefs of Police, 44 Canal Center Plaza, Suite 200, Alexandria, VA 22314, USA a r t i c l e i n f o a b s t r a c t Article history: Background: The Drug Evaluation and Classification Program (DECP) is commonly utilized in driving Received 30 December 2015 under the influence (DUI) cases to help determine category(ies) of impairing drug(s) present in drivers. Received in revised form 8 March 2016 Cannabis, one of the categories, is associated with approximately doubled crash risk. Our objective was Accepted 9 April 2016 to determine the most reliable DECP metrics for identifying cannabis-driving impairment. 9 Methods: We evaluated 302 toxicologically-confirmed (blood -tetrahydrocannabinol [THC] ≥1 ␮g/L) Keywords: cannabis-only DECP cases, wherein examiners successfully identified cannabis, compared to normative Drug Recognition Expert data (302 non-impaired individuals). Physiological measures, pupil size/light reaction, and performance Drug Evaluation and Classification Program Cannabis on psychophysical tests (one leg stand [OLS], walk and turn [WAT], finger to nose [FTN], Modified Romberg Driving Balance [MRB]) were included.
    [Show full text]
  • Evaluation of Divided Attention Psychophysical Task Performance and Effects on Pupil Sizes Following Smoked, Vaporized and Oral
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by DigitalCommons@University of Nebraska University of Nebraska - Lincoln DigitalCommons@University of Nebraska - Lincoln Public Health Resources Public Health Resources 2017 Evaluation of divided attention psychophysical task performance and effects on pupil sizes following smoked, vaporized and oral cannabis administration Matthew .N Newmeyer University of Maryland at Baltimore Madeleine J. Swortwood National Institutes of Health Megan E. Taylor National Institutes of Health Osama A. Abulseoud National Institutes of Health Thomas H. Woodward Maryland State Police See next page for additional authors Follow this and additional works at: http://digitalcommons.unl.edu/publichealthresources Newmeyer, Matthew N.; Swortwood, Madeleine J.; Taylor, Megan E.; Abulseoud, Osama A.; Woodward, Thomas H.; and Huestis, Marilyn A., "Evaluation of divided attention psychophysical task performance and effects on pupil sizes following smoked, vaporized and oral cannabis administration" (2017). Public Health Resources. 532. http://digitalcommons.unl.edu/publichealthresources/532 This Article is brought to you for free and open access by the Public Health Resources at DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in Public Health Resources by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln. Authors Matthew N. Newmeyer, Madeleine J. Swortwood, Megan E. Taylor, Osama A. Abulseoud, Thomas H. Woodward, and Marilyn A. Huestis This article is available at DigitalCommons@University of Nebraska - Lincoln: http://digitalcommons.unl.edu/ publichealthresources/532 Research article Received: 21 November 2016, Revised: 9 December 2016, Accepted: 16 December 2016 Published online in Wiley Online Library: 31 January 2017 (wileyonlinelibrary.com) DOI 10.1002/jat.3440 Evaluation of divided attention psychophysical task performance and effects on pupil sizes following smoked, vaporized and oral cannabis administration Matthew N.
    [Show full text]
  • Dissociative Anesthetics Upon Successfully Completing This
    Participant Manual DRE 7-Day Session 16 – Dissociative Anesthetics Session 16 – Dissociative Anesthetics 100 Minutes Notes:_______________________________________________ _____________________________________________________ Session 16 _____________________________________________________ Dissociative Anesthetics _____________________________________________________ _____________________________________________________ _____________________________________________________ _____________________________________________________ _____________________________________________________ _____________________________________________________ Drug Recognition Expert Course Session 16 – Dissociative Anesthetics Notes:_______________________________________________ Learning Objectives _____________________________________________________ • Explain a brief history of Dissociative Anesthetics and specifically PCP and its _____________________________________________________ analogs • Identify common drug names and terms _____________________________________________________ associated with this drug category • Identify common methods of administration for _____________________________________________________ this drug category _____________________________________________________ • Describe the symptoms, observable signs and other effects associated with this drug category _____________________________________________________ _____________________________________________________ Drug Recognition Expert Course 16-2 _____________________________________________________
    [Show full text]